SCHEMBL15440739

SCHEMBL15440739

CNc1ccc2c(=O)n(CCN(C)C)nc3c2c1C(=O)c1ccccc1-3

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ MITF O75030 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ DNMT1 P26358 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ RAD52 P43351 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ UHRF1 Q96T88 1/20 0.50
▸ ADRA1A P35348 2/20 0.42
▸ HRH1 P35367 2/20 0.42
▸ ADRA1B P35368 2/20 0.42
▸ RXRA P19793 3/20 0.39
▸ TDP1 Q9NUW8 4/20 0.39
▸ EGFR P00533 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PABPC1 P11940 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13468116 0.89 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15440469 0.88 SMN1; SMN2 (0.47) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15449640 0.88 POLB (0.49) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15440706 0.87 KMT2A (0.46) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL13468463 0.87 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15440679 0.85 POLB (0.47) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15440528 0.85 SMN1; SMN2 (0.45) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15440705 0.85 POLB (0.57) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL13281764 0.85 NPC1 (0.52) RAB9ASMN1; SMN2L3MBTL1NPC1MITF
SCHEMBL15440787 0.85 HTT (0.52) RAB9ASMN1; SMN2L3MBTL1NPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096536-B2 Asymmetrically substituted anthrapyridazone derivatives as cytostatics BS-154 S.P. ZO.O. (PL) 2015-08-04 — — US claimed
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS BS-154 SP. Z O.O. (PL) 2014-01-30 — — US claimed
US-9096536-B2 Asymmetrically substituted anthrapyridazone derivatives as cytostatics BS-154 S.P. ZO.O. (PL) 2015-08-04 — — US disclosed
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS BS-154 SP. Z O.O. (PL) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS ABCC1, ABCC3, ABCB1 RAB9A 2277/4885SMN1; SMN2 4813/4885L3MBTL1 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback